Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of “Buy” from Brokerages

Posted by Stanley Muller on Jul 13th, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) has been given a consensus recommendation of “Buy” by the nineteen analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, sixteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $295.6667.

ASND has been the topic of several recent analyst reports. Royal Bank Of Canada boosted their price target on Ascendis Pharma A/S from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Citigroup started coverage on shares of Ascendis Pharma A/S in a research note on Monday, May 18th. They issued a “buy” rating and a $355.00 price objective for the company. Oppenheimer reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Evercore reissued an “outperform” rating and set a $329.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, July 4th.

Check Out Our Latest Stock Report on ASND

Insider Transactions at Ascendis Pharma A/S

In related news, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jean Jacques Bienaime purchased 400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were purchased at an average cost of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the purchase, the director owned 400 shares in the company, valued at $95,120. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 40.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently modified their holdings of the company. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth approximately $26,000. Arax Advisory Partners grew its position in Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 104 shares during the period. Leonteq Securities AG acquired a new stake in Ascendis Pharma A/S in the 4th quarter valued at $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at $42,000. Finally, Global Retirement Partners LLC increased its stake in Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $270.45 on Monday. The business has a 50-day moving average price of $239.99 and a two-hundred day moving average price of $230.29. Ascendis Pharma A/S has a 1-year low of $160.86 and a 1-year high of $282.15. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The company has a market cap of $16.87 billion, a P/E ratio of 31.19 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. As a group, analysts anticipate that Ascendis Pharma A/S will post 4.63 EPS for the current year.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.